Uniphar PLC · EURONEXT:UPR
Uniphar — Shareholder Meeting (May 2022)
36 slides from Uniphar's shareholder meeting presentation, May 11, 2022

Slide 1: Annual General Meeting 2022
Annual General Meeting 2022 Ger Rabbette, CEO 11 May 2022 1

Slide 2: Important Notice
IMPORTANT NOTICE This presentation (hereinafter “this document”) has been prepared by Uniphar plc (the “Company“) for information purposes only. This document has been prepared in good faith but the information contained in it has not been independently verified and does not purport to be comprehens

Slide 3: Overview
OVERVIEW uniphar.ie 3

Slide 4: Uniphar at a Glance
UNIPHAR AT A GLANCE DIVISIONAL GROSS PROFIT A diversified international Strong performance across all divisions with Supply Chain & Retail outperforming medium term divisional guidance healthcare service provider Supporting 200 multinational Organic 200 pharmaceutical and medical manufacturers acros

Slide 5: Track Record
TRACK RECORD STRONG >€86m EVOLUTION TO EBITDA GROWTH INTEGRATED MODEL Fully integrated 40% model Product Access Gross Commercial Profit Margin % Clinical <€10m Supply 2010 Chain 5% EBITDA 2021 EBITDA 2010 2021 2010 2021 GEOGRAPHIC GROSS PROFIT <€50m €274.5m EXPANSION EBITDA <€10m €86.5m LEVERAGE >25

Slide 6: Highlights – 2021
HIGHLIGHTS – 2021 Strong performance with strategic initiatives progressed > Critical role throughout pandemic > Strong financial performance: • EBITDA1 €86.5m (2020: €66.7m) • Adj EPS: 16.2 cent (up 33% LFL) • ROCE 17.6% (2020: 18.7%) > M&A Execution & Integration • 5 acquisitions announced during

Slide 7: Sustainability Highlights
SUSTAINABILITY HIGHLIGHTS Our Charity Sustainable Partners Development Goals INTEGRITY – INCLUSIVITY – LEGACY – STEWARDSHIP - TRANSPARENCY We fully endorse the UN Sustainable Development Goals and consider the PEOPLE & WORKPLACE following goals to be most relevant to > Appointment of Chief People Of

Slide 8: Divisional Review
DIVISIONAL REVIEW uniphar.ie 8

Slide 9: Divisional Objectives
DIVISIONAL OBJECTIVES Commercial Product Supply Chain & Clinical Access & Retail Pan-European Platform Market Leadership Market Share Therapeutic Expertise Patient Centricity Operational Optimisation Omni-Channel Enabled Subject Matter Expertise Symbol Group Leadership H1 2021 Results Presentation 0

Slide 10: Commercial & Clinical: Scaling in Europe
COMMERCIAL & CLINICAL SCALING IN EUROPE Currently Active 10% Entered in 2021 PAN-EUROPEAN PLATFORM Medium term target expansion M&A and Organic Strategy > Serving 15 Countries, focused on expansion > Growing US services into Europe > M&A accelerating service offering THERAPEUTIC FOCUS Market Specifi

Slide 11: Commercial & Clinical
COMMERCIAL Sales, marketing and Building a pan-European service offering from & CLINICAL distribution solutions our present footprint in Ireland, the UK, Germany, for manufacturers Benelux, the Nordics & the US Gross Profit Revenue Gross Profit Financials €299.9m €104.4m 2020 Reported 2021 Reported

Slide 12: Product Access: Global Capabilities
PRODUCT ACCESS 10% GLOBAL CAPABILITIES MARKET LEADERSHIP Continued Double Digit Organic Growth 42% > Global platform fuelling growth > Leveraging M&A to accelerate market leadership SUBJECT MATTER EXPERTISE Focus on Specialty Pharma > Continue to expand our therapeutic focus into specialised & compl

Slide 13: Product Access
PRODUCT Providing access to Platform in place to become a global ACCESS unlicensed and speciality leader in the provision of On Demand medicines globally and Exclusive Access services Gross Profit Revenue Gross Profit Financials €157.2m €41.3m 2020 Reported 2021 Reported Organic Gross Profit Reporte

Slide 14: Supply Chain & Retail: Market Leadership
SUPPLY CHAIN & RETAIL MARKET LEADERSHIP SC&R: Market Share Growth(1) MARKET SHARE 2010 Growth Trajectory; Market share >50% 42% > Organic investment underpinning growth 2021 > Positive gross margin trajectory remains in focus > M&A broadening offering and fuelling growth 0% 50% OPERATIONAL OPTIMISAT

Slide 15: Supply Chain & Retail
Market leader in Irish Leverage high-tech distribution facilities, SUPPLY CHAIN wholesale and hospital longstanding manufacturer relationships & RETAIL market. Supported by a and scalable digital infrastructure network of 378 pharmacies.(1) Uniphar Volume Growth vs Market Volume Growth Revenue Gross

Slide 16: Capital Allocation, Outlook & Investment Case
CAPITAL ALLOCATION, OUTLOOK & INVESTMENT CASE uniphar.ie 16

Slide 17: Strategic Acquisitions
STRATEGIC ACQUISITIONS Strong M&A discipline within the Group complements continued organic Transformational Acquisitions growth focus 2013 2018 2019 Acquisition Pipeline Criteria Strategic alignment in identified growth segments Strategic Acquisitions Retention of management talent and expertise Cu

Slide 18: Capital Allocation
Disciplined & balanced investment approach CAPITAL ALLOCATION ORGANIC INVESTMENT > Continue to invest in infrastructure, digital platforms, strategic capex and talent to drive organic growth in line with medium term guidance M&A > Fundamental component of compounding growth strategy > Focussed on fu

Slide 19: Medium Term Outlook Unchanged & 2022 Expected to Deliver on Plan
MEDIUM TERM OUTLOOK UNCHANGED & 2022 EXPECTED TO DELIVER ON PLAN Divisional Guidance | Medium term Group Guidance | Medium term metrics organic growth in gross profit: PRODUCT ACCESS ROCE FCF Conversion Double Digit 12 - 15% 60% - 70% COMMERCIAL & CLINICAL Mid Single Digit Dividend Net Bank Debt / E

Slide 20: Uniphar Group
&suniphar group

Slide 21: Resolutions
RESOLUTIONS uniphar.ie 21

Slide 22: Resolutions
RESOLUTIONS Resolutions 1 to 5 are proposed as ordinary resolutions and require a simple majority to be passed. Resolutions 6 to 10 are proposed as special resolutions which to be passed require a majority of at least 75% to vote in favour. Resolution 1: To receive and consider the Company's financi

Slide 23: Resolutions
RESOLUTIONS Resolution 5: That the Directors are hereby unconditionally authorised to exercise all the powers of the Company to allot relevant securities (within the meaning of Section 1021 of the Companies Act 2014) up to an aggregate nominal amount of: (a) €7,207,601.84 (90,095,023 Ordinary Shares

Slide 24: Resolutions
RESOLUTIONS Resolution 6 io approve the dis-application of pre-emption rights in specified circumstances. That, subject to the approval of Resolution 5 in the Notice of this meeting, the Directors are hereby empowered pursuant to Sections 1022 and 1023 of the Companies Act 2014 to allot equity secur

Slide 25: Resolutions
RESOLUTIONS Resolution 7 That, subject to the approval of Resolution 5 in the Notice of this meeting, the Directors are hereby authorised in addition to any authority granted under Resolution 6 in the Notice of this meeting to allot equity securities (as defined in Section 1023 of the Companies Act

Slide 26: Resolutions
RESOLUTIONS Resolution 8 That the Company and/or any subsidiary (as defined by Section 7 of the Companies Act 2014) of the Company is hereby generally authorised to make market purchases and overseas market purchases (as defined by Section 1072 of the Companies Act 2014) Ordinary Shares on such term

Slide 27: Resolutions
RESOLUTIONS Resolution 9 That, subject to the passing of Resolution 8 in the Notice of this meeting, for the purposes of Section 1078 of the Companies Act 2014, the re-issue price range at which any treasury shares (as defined in Section 106 of the Companies Act 2014) for the time being held by the

Slide 28: Resolutions
RESOLUTIONS Resolution 10 That the Articles of Association of the Company be amended by: (a) the deletion in the existing Article 54(b) and the existing Article 79(d) of the words "by rotation or otherwise; (b) the deletion in the existing Article 74 of the words "and he shall not retire by rotation

Slide 29: Thank You
UNIPHAR.IE THANK YOU Uniphar.ie 29

Slide 30: Appendices
APPENDICES uniphar.ie == 30

Slide 31: Financial Review
FINANCIAL REVIEW uniphar.ie 31

Slide 32: Divisional Gross Profit
DIVISIONAL GROSS PROFIT DIVISIONAL COMPOSITION Diversified healthcare services business focused on higher margin opportunities 47% Organic 2021 2021 2020 Growth Growth €274.5m €’m €’m % % GP Commercial & Clinical 104.4 92.2 13.2% 7.9% 15% 38% Product Access 41.3 30.4 35.8% 19.9% Supply Chain & Retai

Slide 33: Liquidity and Banking Facilities
LIQUIDITY BANKING FACILITIES ✓ Ample facility limits 31/12/2021 €’m ✓ Competitive interest rate Cash & Cash equivalents 78.0 ✓ Revolver ✓ Multi-currency Bank Borrowings (126.3) ✓ 2025 Renewal Net Bank Debt (48.3) ✓ Addition of two international partners (RBC and HSBC) Facilities €’m Strong liquidity

Slide 34: Shareholder Returns Since IPO
SHAREHOLDER RETURNS SINCE IPO UNIPHAR PLC 6 Price 5 Eur 4 IPO 1.15 3 High 5.00 2 Low 0.98 1 07th May 2021 3.70 0 2021 Results Presentation 09/05/2022 uniphar.ie 34

Slide 35: Investment Case
INVESTMENT CASE COMPELLING MARKET OPPORTUNITY • Increasing requirements for speciality products • Continued growth in outsourcing EXPERIENCED by manufacturers INDUSTRY TEAM • Highly fragmented European market Experienced Compelling • Executive management, line Industry Market management and specialt

Slide 36: Contact Details
Uniphar.ie CONTACT DETAILS Seamus Egan Head of Corporate Development & IR +353 (0)1 428 7777 investor.relations@Uniphar.ie Q4 PR Public Relations Adviser to Uniphar Iarla Mongey +353 (0)1 475 1444; or +353 (0)87 235 6461 36
Source: Internet Archive copy of uniphar.ie
More decks from Uniphar PLC
H1 2026 Earnings Presentation39 slides · Sep 8, 2026
FY2025 Earnings Presentation39 slides · Feb 24, 2026
FY2024 Earnings Presentation38 slides · Feb 25, 2025
H1 2024 Earnings Presentation37 slides · Sep 3, 2024
FY2023 Earnings Presentation39 slides · Feb 27, 2024
H1 2023 Earnings Presentation41 slides · Sep 14, 2023